Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NUVL with free AI briefings, catalyst countdowns, and dilution alerts.

NUVL · Nuvalent, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Acquired. Nuvalent was acquired: the merger closed on Jul 15, 2026 and NUVL was delisted. The data below is from before the deal. Read the filing
$1.3B Cash on Hand
46.6mo Cash Runway
6.2% Short Interest
$124 Analyst Target (9)
Follow NUVL by email Get an email when NUVL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NUVL, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zidesamtinib (NVL-520)
FDA approved Jul 2026 · Jideytro
Locally Advanced Solid Tumor Phase 1/2 · NCT05118789 Recruiting
Alectinib Non-small Cell Lung Cancer Phase 3 · NCT06765109 Recruiting
ALK Inhibitor NVL-655 Non-small Cell Lung Cancer Phase 3 · NCT06765109 Recruiting
HER2 Mutant-selective Inhibitor NVL-330 Locally Advanced Solid Tumor Phase 1 · NCT06521554 Recruiting

Also used in these trials (approved or third-party drugs, not NUVL's own candidates): Itraconazole, Midazolam Hydrochloride, Repaglinide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NUVL holds $1.3B in cash and short-term investments (as of Mar 31, 2026) and burns about $82.9M/quarter from operations, an estimated runway of 46.6 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUVL files for a raise →

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-07-15
filed 2026-07-15
Noci Darlene
Returned to issuer (D) 14,350 – 0
2026-07-15
filed 2026-07-15
Turner Christopher Durant
Other (U) 31,530 $124.00 0
2026-07-15
filed 2026-07-15
Noci Darlene
Returned to issuer (D) 17,500 – –
2026-07-15
filed 2026-07-15
Noci Darlene
Returned to issuer (D) 37,500 – –
2026-07-15
filed 2026-07-15
Noci Darlene
Returned to issuer (D) 33,646 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-07-22 zidesamtinib (Jideytro) NDA — — —

Browse all historical PDUFA outcomes →

Get the full NUVL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUVL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.